Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis

Clin Cancer Res. 2005 Apr 1;11(7):2568-75. doi: 10.1158/1078-0432.CCR-04-2039.

Abstract

Purpose: Pancreatitis-associated protein (PAP) and regenerating protein 1 alpha (Reg1A) are up-regulated during the pancreas regeneration. This study is to investigate the clinicopathologic denotation of their expression in hepatocellular carcinoma (HCC).

Experimental design: PAP and REG1A mRNA levels were measured in 265 surgically removed unifocal primary HCCs using reverse transcription-PCR.

Results: PAP and REG1A mRNAs were detected in 97 (36.6%) and 55 (20.8%) HCCs, respectively, including 46 with coexpression but in none of the 219 nontumorous livers. HCCs with PAP expression correlated with low-stage tumors without evidence of vascular invasion (P = 0.013) but the REG1A expression did not. By a combination analysis, HCCs with PAP expression alone showed the lowest frequency of p53 mutation (P < 0.036), the highest rates of grade 1 and low-stage tumors (P < 0.007 and P < 0.001, respectively), less frequent early tumor recurrence (P = 0.051), and hence a better 5-year survival (P = 0.044) than groups expressing PAP and REG1A, REG1A alone, and neither PAP or REG1A. Besides, PAP expressing HCCs had significantly frequent beta-catenin mutation, regardless of REG1A expression, P < 0.00001. In the subset of HCCs that has no mutations of p53 and beta-catenin but showed PAP expression, coexpression of REG1A and PAP was associated with more frequent vascular invasion than PAP expression alone (P < 0.005).

Conclusions: These data suggest that PAP expression designate a subset of low-grade, low-stage HCC with frequent beta-catenin mutation and hence more favorable prognosis, whereas further genetic or epigenetic alterations, such as p53 mutation and REG1A expression, lead to more advanced HCCs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm / genetics*
  • Biomarkers, Tumor / genetics*
  • Calcium-Binding Proteins / genetics*
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / pathology*
  • Cytoskeletal Proteins / genetics
  • Disease Progression
  • Female
  • Gene Expression Regulation, Neoplastic / physiology
  • Humans
  • Lectins, C-Type / genetics*
  • Lithostathine
  • Liver Neoplasms / genetics
  • Liver Neoplasms / pathology*
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Nerve Tissue Proteins / genetics*
  • Pancreatitis-Associated Proteins
  • Prognosis
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Survival Analysis
  • Trans-Activators / genetics
  • Tumor Suppressor Protein p53 / genetics
  • beta Catenin

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • CTNNB1 protein, human
  • Calcium-Binding Proteins
  • Cytoskeletal Proteins
  • Lectins, C-Type
  • Lithostathine
  • Nerve Tissue Proteins
  • Pancreatitis-Associated Proteins
  • REG1A protein, human
  • REG3A protein, human
  • RNA, Messenger
  • Trans-Activators
  • Tumor Suppressor Protein p53
  • beta Catenin